Physician profile
James Shou
NPI 1881000271
$6,753.42
in general payments reported to CMS, 2019-2025
28 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $385 · 2021: $264 · 2022: $483 · 2023: $1,620 · 2024: $1,564 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,001 · Travel and Lodging: $660 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,001.09 |
| Travel and Lodging | $659.50 |
| Education | $255.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,242.75 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $763.24 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amneal Pharmaceuticals LLC | $755.02 | 2020-2025 | Crexont, Rytary |
| Abbvie INC. | $623.34 | 2023-2025 | Ubrelvy, Duopa |
| Medtronic USA, INC. | $503.46 | 2019-2020 | |
| Abbott Laboratories | $394.19 | 2019-2024 | Eterna |
| Tg Therapeutics, INC. | $364.97 | 2025 | |
| Mdd US Operations, LLC | $225.68 | 2024-2025 | Gocovri |
| Pfizer INC. | $225.02 | 2022-2025 | |
| Genentech USA, INC. | $218.05 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Neurocrine Biosciences, INC. | $180.33 | 2024-2025 | Ingrezza |
| Celgene Corporation | $154.62 | 2023-2025 | Zeposia |
| Lilly USA, LLC | $147.63 | 2022-2024 | Reyvow, Emgality, Amyvid |
| Lundbeck LLC | $124.80 | 2019 | |
| Merz Pharmaceuticals, LLC | $115.26 | 2022-2025 | Xeomin |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $104.74 | 2022-2024 | Nourianz |
| Acorda Therapeutics, INC | $99.60 | 2019 | |
| Axsome Therapeutics, INC. | $96.81 | 2025 | Symbravo |
| Ucb, INC. | $77.33 | 2024 | Fintepla, Nayzilam |
| Nevro Corp. | $48.74 | 2023-2024 | Senza |
| Acadia Pharmaceuticals INC | $47.54 | 2019 | |
| Averitas Pharma INC. | $47.23 | 2025 | Qutenza |
| Biogen, INC. | $42.42 | 2021 | |
| Csl Behring | $42.13 | 2024 | Hizentra |
| Novartis Pharmaceuticals Corporation | $32.51 | 2021-2023 | |
| Genzyme Corporation | $31.47 | 2025 | |
| Supernus Pharmaceuticals, INC. | $23.34 | 2025 | Qelbree |
| Alexion Pharmaceuticals, INC. | $21.20 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Shou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.